WallStreetZenWallStreetZen

NASDAQ: CRDF
Cardiff Oncology Inc Stock Forecast, Predictions & Price Target

Analyst price target for CRDF

Based on 2 analysts offering 12 month price targets for Cardiff Oncology Inc.
Min Forecast
$7.00+197.87%
Avg Forecast
$10.50+346.81%
Max Forecast
$14.00+495.74%

Should I buy or sell CRDF stock?

Based on 2 analysts offering ratings for Cardiff Oncology Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CRDF stock forecasts and price targets.

CRDF stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-06
lockedlocked$00.00+00.00%2024-03-01

1 of 1

Forecast return on equity

Is CRDF forecast to generate an efficient return?
Company
-135.88%
Industry
71.46%
Market
80.46%
CRDF's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CRDF forecast to generate an efficient return on assets?
Company
-111.75%
Industry
30.8%
CRDF is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CRDF earnings per share forecast

What is CRDF's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$0.98
Avg 2 year Forecast
-$1.06
Avg 3 year Forecast
-$1.54

CRDF revenue forecast

What is CRDF's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$455.0k-25.41%
Avg 2 year Forecast
$200.0k-67.21%
Avg 3 year Forecast
$200.0k-67.21%
CRDF's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CRDF revenue growth forecast

How is CRDF forecast to perform vs Biotechnology companies and vs the US market?
Company
-37.05%
Industry
64.18%
Market
11.31%
CRDF's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CRDF's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CRDF vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CRDF$2.35$10.50+346.81%Strong Buy
ORMP$2.59N/AN/A
VTGN$3.92N/AN/A
ELDN$2.76$16.00+479.71%Buy
KPTI$0.91$7.00+668.39%Buy

Cardiff Oncology Stock Forecast FAQ

Is Cardiff Oncology Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CRDF) stock is to Strong Buy CRDF stock.

Out of 2 analysts, 1 (50%) are recommending CRDF as a Strong Buy, 1 (50%) are recommending CRDF as a Buy, 0 (0%) are recommending CRDF as a Hold, 0 (0%) are recommending CRDF as a Sell, and 0 (0%) are recommending CRDF as a Strong Sell.

If you're new to stock investing, here's how to buy Cardiff Oncology stock.

What is CRDF's earnings growth forecast for 2024-2026?

(NASDAQ: CRDF) Cardiff Oncology's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.27%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.64%.

Cardiff Oncology's earnings in 2024 is -$40,253,000.On average, 4 Wall Street analysts forecast CRDF's earnings for 2024 to be -$43,718,288, with the lowest CRDF earnings forecast at -$46,513,575, and the highest CRDF earnings forecast at -$38,015,902. On average, 3 Wall Street analysts forecast CRDF's earnings for 2025 to be -$47,408,066, with the lowest CRDF earnings forecast at -$53,222,263, and the highest CRDF earnings forecast at -$35,779,673.

In 2026, CRDF is forecast to generate -$68,875,870 in earnings, with the lowest earnings forecast at -$68,875,870 and the highest earnings forecast at -$68,875,870.

What is CRDF's revenue growth forecast for 2024-2026?

(NASDAQ: CRDF) Cardiff Oncology's forecast annual revenue growth rate of -37.05% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.31%.

Cardiff Oncology's revenue in 2024 is $610,000.On average, 3 Wall Street analysts forecast CRDF's revenue for 2024 to be $20,349,689, with the lowest CRDF revenue forecast at $8,944,918, and the highest CRDF revenue forecast at $36,226,919. On average, 1 Wall Street analysts forecast CRDF's revenue for 2025 to be $8,944,918, with the lowest CRDF revenue forecast at $8,944,918, and the highest CRDF revenue forecast at $8,944,918.

In 2026, CRDF is forecast to generate $8,944,918 in revenue, with the lowest revenue forecast at $8,944,918 and the highest revenue forecast at $8,944,918.

What is CRDF's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CRDF) forecast ROA is -111.75%, which is lower than the forecast US Biotechnology industry average of 30.8%.

What is CRDF's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CRDF price target, the average CRDF price target is $10.50, with the highest CRDF stock price forecast at $14.00 and the lowest CRDF stock price forecast at $7.00.

On average, Wall Street analysts predict that Cardiff Oncology's share price could reach $10.50 by May 6, 2025. The average Cardiff Oncology stock price prediction forecasts a potential upside of 346.81% from the current CRDF share price of $2.35.

What is CRDF's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: CRDF) Cardiff Oncology's current Earnings Per Share (EPS) is -$0.90. On average, analysts forecast that CRDF's EPS will be -$0.98 for 2024, with the lowest EPS forecast at -$1.04, and the highest EPS forecast at -$0.85. On average, analysts forecast that CRDF's EPS will be -$1.06 for 2025, with the lowest EPS forecast at -$1.19, and the highest EPS forecast at -$0.80. In 2026, CRDF's EPS is forecast to hit -$1.54 (min: -$1.54, max: -$1.54).

What is CRDF's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CRDF) forecast ROE is -135.88%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.